{"id":956320,"date":"2026-04-29T20:58:02","date_gmt":"2026-04-30T00:58:02","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/mesoblast-reports-ryoncil-net-revenues-of-us30-3m-and-improved-net-operating-cash-spend-for-the-quarter-to-us4-1-million\/"},"modified":"2026-04-29T20:58:02","modified_gmt":"2026-04-30T00:58:02","slug":"mesoblast-reports-ryoncil-net-revenues-of-us30-3m-and-improved-net-operating-cash-spend-for-the-quarter-to-us4-1-million","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/mesoblast-reports-ryoncil-net-revenues-of-us30-3m-and-improved-net-operating-cash-spend-for-the-quarter-to-us4-1-million\/","title":{"rendered":"Mesoblast Reports Ryoncil\u00ae Net Revenues of US$30.3m and Improved Net Operating Cash Spend for the Quarter to US$4.1 Million"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <em>Achieved Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain<\/em>\n      <\/p>\n<p align=\"center\">\n        <em>Activity Report for Quarter Ended March 31, 2026 (Appendix 4C)<\/em>\n      <\/p>\n<p align=\"justify\">NEW YORK, April  29, 2026  (GLOBE NEWSWIRE) &#8212; Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided highlights of its recent activities for the third fiscal quarter ended March 31, 2026.<\/p>\n<p align=\"justify\">\u201cWe\u2019ve had a busy and exciting March quarter marked by a series of major achievements. Ryoncil<sup>\u00ae<\/sup> revenues are now approaching US$100 million since last year\u2019s launch, we have substantially improved our net operating cash spend, our pivotal trial in inflammatory back pain has successfully achieved its patient recruitment target, and we have bolstered our long-term leadership in the field by acquiring genetically modified technology for precision-enhanced cell therapy products,\u201d said Dr. Silviu Itescu, Mesoblast Chief Executive.<\/p>\n<p align=\"justify\">\n        <strong>FINANCIAL HIGHLIGHTS FOR QUARTER ENDED MARCH 31, 2026<\/strong><br \/>\n        <sup><br \/>\n          <strong>1<\/strong><br \/>\n        <\/sup>\n      <\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:6pt;text-align:justify\">Ryoncil<sup>\u00ae<\/sup> gross sales for the quarter were US$35.3 million, and net revenues were US$30.3 million.<sup>1<\/sup><\/li>\n<li style=\"margin-top:6pt;text-align:justify\">Strong sales in February and March offset holiday seasonality in January.<\/li>\n<li style=\"margin-top:6pt;text-align:justify\">Revenue generated during this first year of Ryoncil<sup>\u00ae<\/sup> launch approaches US$100 million.<\/li>\n<li style=\"margin-top:6pt;text-align:justify\">Net operating cash spend for the quarter was US$4.1 million. The reduction in net operating cash spend was driven by receipts of US$34.6 million and tight control of operating expenses.<\/li>\n<li style=\"margin-top:6pt;text-align:justify\">Mesoblast had US$122 million of cash at March 31, 2026.\n<\/li>\n<\/ul>\n<p align=\"justify\">\n        <strong>OPERATIONAL HIGHLIGHTS <\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:6pt;text-align:justify\">Achieved patient recruitment target in pivotal phase 3 trial of second-generation product rexlemestrocel-L for chronic low back pain (CLBP).<\/li>\n<li style=\"margin-top:6pt;text-align:justify\">Held inaugural R&amp;D day on April 8<sup>th<\/sup> in New York. A replay of the event is available <a href=\"https:\/\/webcast.openbriefing.com\/msb-inv-2026\/\" rel=\"nofollow\" target=\"_blank\">here<\/a> and presentation materials <a href=\"https:\/\/investorsmedia.mesoblast.com\/static-files\/3eb78f1f-f0d0-4913-bbad-98f4c0e94c96\" rel=\"nofollow\" target=\"_blank\">here<\/a>.<\/li>\n<li style=\"margin-top:6pt;text-align:justify\">At the R&amp;D day Mesoblast highlighted its label extension strategy for Ryoncil<sup>\u00ae<\/sup> in adult and pediatric rare diseases, provided an update on near- and mid-term blockbuster opportunities in inflammatory back pain and heart failure, showcased leadership in allogeneic cell therapy innovation, and outlined commercial strategies for continued revenue growth.<\/li>\n<li style=\"margin-top:6pt;text-align:justify\">The trial for label extension of our flagship product Ryoncil<sup>\u00ae<\/sup> in adults with SR-aGvHD was cleared to begin by FDA, by data safety monitoring board (DSMB), and by central institutional review board (IRB) with first sites to be activated this quarter.<\/li>\n<li style=\"margin-top:6pt;text-align:justify\">FDA granted Investigational New Drug (IND) clearance to proceed directly to a registrational trial evaluating Ryoncil<sup>\u00ae<\/sup> in Duchenne\u2019s muscular dystrophy (DMD), which affects approximately 15,000 children in the U.S.<\/li>\n<li style=\"margin-top:6pt;text-align:justify\">In addition, at the R&amp;D day, Mesoblast unveiled next generation mesenchymal stromal cell (MSC) strategies including announcing the acquisition of an exclusive worldwide license to a patented chimeric antigen receptor (CAR) technology platform for precision-enhanced augmentation of therapeutic MSC products.<\/li>\n<li style=\"margin-top:6pt;text-align:justify\">This CAR technology provides Mesoblast with an immediate opportunity to generate products with even greater potency for ulcerative colitis or Crohn&#8217;s disease. In addition, Mesoblast plans to use CAR-MSC engineered to express CD19 on their surface to induce remission in Lupus Nephritis and other B cell autoimmune diseases where durable, effective and safe immunomodulation is highly desirable.\n<\/li>\n<\/ul>\n<p align=\"justify\">\n        <strong>Other <\/strong><br \/>\n        <br \/>Fees to Non-Executive Directors were US$156,048, consulting payments to Non-Executive Directors were US$150,000, and salary payments to full-time Executive Directors were US$399,070, detailed in Item 6 of the Appendix 4C cash flow report for the quarter.<sup>2<\/sup><\/p>\n<p>A copy of the Appendix 4C \u2013 Quarterly Cash Flow Report for the third quarter FY2026 is available on the investor page of the company\u2019s website <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=D-jUprwoTaJTEJTLOMKhB0VsOv88YD4XKrjDLfM9o_y-dW4-K4lmIio_hgTTxKS9Gf1tlU4Nb9_loFkawisuUvZaO4Hasm87A_xSxFNHDEo=\" rel=\"nofollow\" target=\"_blank\">www.mesoblast.com<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>About Mesoblast <\/strong><br \/>\n        <br \/>Mesoblast (the Company) is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The therapies from the Company\u2019s proprietary mesenchymal lineage cell therapy technology platform respond to severe inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, resulting in significant reduction of the damaging inflammatory process.<\/p>\n<p align=\"justify\">Mesoblast\u2019s Ryoncil<sup>\u00ae<\/sup> (remestemcel-L-rknd) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA-approved mesenchymal stromal cell (MSC) therapy. Please see the full Prescribing Information at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=g-luXAuxH1ldxDyRmgeQnh4MLNlIg78ISwvv4L3kqJGHZMM35tMFPg6T0ccfQFVF5EfES-8T9ZpJRs0oAdcvQJKNEksuCqIdUvVlEj6gETk=\" rel=\"nofollow\" target=\"_blank\">www.ryoncil.com<\/a>.<\/p>\n<p align=\"justify\">Mesoblast is committed to developing additional cell therapies for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Ryoncil<sup>\u00ae<\/sup> is being developed for additional inflammatory diseases including SR-aGvHD in adults and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for heart failure and chronic low back pain. The Company has established commercial partnerships in Japan, Europe and China.<\/p>\n<p align=\"justify\">\n        <strong>About Mesoblast intellectual property: <\/strong>Mesoblast has a strong and extensive global intellectual property portfolio, with over 1,000 granted patents or patent applications covering mesenchymal stromal cell compositions of matter, methods of manufacturing and indications. These granted patents and patent applications provide commercial protection extending through to at least 2044 in all major markets.<\/p>\n<p align=\"justify\">\n        <strong>About Mesoblast manufacturing: <\/strong>The Company\u2019s proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide.<\/p>\n<p align=\"justify\">Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=D-jUprwoTaJTEJTLOMKhB0K9sHfmXTc5xTlsKGVdZaqZ3Kq6iwF6Bu_3qITw8T4lyHhnYGgOyFSnWJZHviftUTJGRyqlzcPe5Ukt8EODVos=\" rel=\"nofollow\" target=\"_blank\">www.mesoblast.com<\/a>, LinkedIn: Mesoblast Limited and Twitter: @Mesoblast<\/p>\n<p align=\"justify\">\n        <strong>References \/ Footnotes<\/strong>\n      <\/p>\n<ol style=\"list-style-type:decimal\">\n<li style=\"text-align:justify\">The revenues included in this press release are based on management\u2019s initial analysis of operations for the third quarter ended March 31, 2026, and are subject to completion of Mesoblast\u2019s financial closing procedures and audit.<\/li>\n<li style=\"text-align:justify\">As required by ASX listing rule 4.7 and reported in Item 6 of the Appendix 4C, reported are the aggregated total payments to related parties being Executive Directors and Non-Executive Directors.\n<\/li>\n<\/ol>\n<p align=\"justify\">\n        <strong>Forward-Looking Statements<\/strong><br \/>\n        <br \/>This press release includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements should not be read as a guarantee of future performance or results, and actual results may differ from the results anticipated in these forward-looking statements, and the differences may be material and adverse. Forward-looking statements include, but are not limited to, statements about: the initiation, timing, progress and results of Mesoblast\u2019s preclinical and clinical studies, and Mesoblast\u2019s research and development programs; Mesoblast\u2019s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; Mesoblast\u2019s ability to advance its manufacturing capabilities; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities, if any; the commercialization of Mesoblast\u2019s RYONCIL for pediatric SR-aGVHD and any other product candidates, if approved; regulatory or public perceptions and market acceptance surrounding the use of stem-cell based therapies; the potential for Mesoblast\u2019s product candidates, if any are approved, to be withdrawn from the market due to patient adverse events or deaths; the potential benefits of strategic collaboration agreements and Mesoblast\u2019s ability to enter into and maintain established strategic collaborations; Mesoblast\u2019s ability to establish and maintain intellectual property on its product candidates and Mesoblast\u2019s ability to successfully defend these in cases of alleged infringement; the scope of protection Mesoblast is able to establish and maintain for intellectual property rights covering its product candidates and technology; estimates of Mesoblast\u2019s expenses, future revenues, capital requirements and its needs for additional financing; Mesoblast\u2019s financial performance; developments relating to Mesoblast\u2019s competitors and industry; and the pricing and reimbursement of Mesoblast\u2019s product candidates, if approved. You should read this press release together with our risk factors, in our most recently filed reports with the SEC or on our website. Uncertainties and risks that may cause Mesoblast\u2019s actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, and accordingly, you should not place undue reliance on these forward-looking statements. We do not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.<\/p>\n<p align=\"justify\">Release authorized by the Chief Executive.<\/p>\n<p align=\"justify\">\n        <em>For more information, please contact:<\/em>\n      <\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: top\">\n            <strong><br \/>\n              <em>Corporate Communications \/ Investors<\/em><br \/>\n            <\/strong>\n          <\/td>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: top\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: top\">Paul Hughes<\/td>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: top\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: top\">T: +61 3 9639 6036<\/td>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: top\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: top\">\u00a0<\/td>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: top\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: top\">\n            <strong><br \/>\n              <em>Media \u2013 Global <\/em><br \/>\n            <\/strong>\n          <\/td>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: top\">\n            <strong><br \/>\n              <em>Media \u2013 Australia<\/em><br \/>\n            <\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: top\">Rubenstein<\/td>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: top\">BlueDot Media<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: top\">Caroline Nelson<\/td>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: top\">Steve Dabkowski<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: top\">T: +1 703 489 3037<\/td>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: top\">T: +61 419 880 486<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: top\">E: <a href=\"mailto:cnelson@rubenstein.com\" rel=\"nofollow\" target=\"_blank\">cnelson@rubenstein.com<\/a><\/td>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: top\">E: <a href=\"mailto:steve@bluedot.net.au\" rel=\"nofollow\" target=\"_blank\">steve@bluedot.net.au<\/a><\/td>\n<\/tr>\n<\/table>\n<p>\n        \n      <\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxMDE0MCM3NTc0ODI3IzIwMTc0MzI=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NTAyN2FjZmEtNjFmNy00NmU0LTlkNjUtMzAxZGUzODVmZWI0LTEwMjkwMDUtMjAyNi0wNC0zMC1lbg==\/tiny\/Mesoblast-Limited.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Achieved Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain Activity Report for Quarter Ended March 31, 2026 (Appendix 4C) NEW YORK, April 29, 2026 (GLOBE NEWSWIRE) &#8212; Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided highlights of its recent activities for the third fiscal quarter ended March 31, 2026. \u201cWe\u2019ve had a busy and exciting March quarter marked by a series of major achievements. Ryoncil\u00ae revenues are now approaching US$100 million since last year\u2019s launch, we have substantially improved our net operating cash spend, our pivotal trial in inflammatory back pain has successfully achieved its patient recruitment target, and we have bolstered our long-term leadership in the field &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/mesoblast-reports-ryoncil-net-revenues-of-us30-3m-and-improved-net-operating-cash-spend-for-the-quarter-to-us4-1-million\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Mesoblast Reports Ryoncil\u00ae Net Revenues of US$30.3m and Improved Net Operating Cash Spend for the Quarter to US$4.1 Million&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-956320","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Mesoblast Reports Ryoncil\u00ae Net Revenues of US$30.3m and Improved Net Operating Cash Spend for the Quarter to US$4.1 Million - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/mesoblast-reports-ryoncil-net-revenues-of-us30-3m-and-improved-net-operating-cash-spend-for-the-quarter-to-us4-1-million\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Mesoblast Reports Ryoncil\u00ae Net Revenues of US$30.3m and Improved Net Operating Cash Spend for the Quarter to US$4.1 Million - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Achieved Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain Activity Report for Quarter Ended March 31, 2026 (Appendix 4C) NEW YORK, April 29, 2026 (GLOBE NEWSWIRE) &#8212; Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided highlights of its recent activities for the third fiscal quarter ended March 31, 2026. \u201cWe\u2019ve had a busy and exciting March quarter marked by a series of major achievements. Ryoncil\u00ae revenues are now approaching US$100 million since last year\u2019s launch, we have substantially improved our net operating cash spend, our pivotal trial in inflammatory back pain has successfully achieved its patient recruitment target, and we have bolstered our long-term leadership in the field &hellip; Continue reading &quot;Mesoblast Reports Ryoncil\u00ae Net Revenues of US$30.3m and Improved Net Operating Cash Spend for the Quarter to US$4.1 Million&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/mesoblast-reports-ryoncil-net-revenues-of-us30-3m-and-improved-net-operating-cash-spend-for-the-quarter-to-us4-1-million\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-30T00:58:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxMDE0MCM3NTc0ODI3IzIwMTc0MzI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mesoblast-reports-ryoncil-net-revenues-of-us30-3m-and-improved-net-operating-cash-spend-for-the-quarter-to-us4-1-million\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mesoblast-reports-ryoncil-net-revenues-of-us30-3m-and-improved-net-operating-cash-spend-for-the-quarter-to-us4-1-million\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Mesoblast Reports Ryoncil\u00ae Net Revenues of US$30.3m and Improved Net Operating Cash Spend for the Quarter to US$4.1 Million\",\"datePublished\":\"2026-04-30T00:58:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mesoblast-reports-ryoncil-net-revenues-of-us30-3m-and-improved-net-operating-cash-spend-for-the-quarter-to-us4-1-million\\\/\"},\"wordCount\":1399,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mesoblast-reports-ryoncil-net-revenues-of-us30-3m-and-improved-net-operating-cash-spend-for-the-quarter-to-us4-1-million\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxMDE0MCM3NTc0ODI3IzIwMTc0MzI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mesoblast-reports-ryoncil-net-revenues-of-us30-3m-and-improved-net-operating-cash-spend-for-the-quarter-to-us4-1-million\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mesoblast-reports-ryoncil-net-revenues-of-us30-3m-and-improved-net-operating-cash-spend-for-the-quarter-to-us4-1-million\\\/\",\"name\":\"Mesoblast Reports Ryoncil\u00ae Net Revenues of US$30.3m and Improved Net Operating Cash Spend for the Quarter to US$4.1 Million - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mesoblast-reports-ryoncil-net-revenues-of-us30-3m-and-improved-net-operating-cash-spend-for-the-quarter-to-us4-1-million\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mesoblast-reports-ryoncil-net-revenues-of-us30-3m-and-improved-net-operating-cash-spend-for-the-quarter-to-us4-1-million\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxMDE0MCM3NTc0ODI3IzIwMTc0MzI=\",\"datePublished\":\"2026-04-30T00:58:02+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mesoblast-reports-ryoncil-net-revenues-of-us30-3m-and-improved-net-operating-cash-spend-for-the-quarter-to-us4-1-million\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mesoblast-reports-ryoncil-net-revenues-of-us30-3m-and-improved-net-operating-cash-spend-for-the-quarter-to-us4-1-million\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mesoblast-reports-ryoncil-net-revenues-of-us30-3m-and-improved-net-operating-cash-spend-for-the-quarter-to-us4-1-million\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxMDE0MCM3NTc0ODI3IzIwMTc0MzI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxMDE0MCM3NTc0ODI3IzIwMTc0MzI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mesoblast-reports-ryoncil-net-revenues-of-us30-3m-and-improved-net-operating-cash-spend-for-the-quarter-to-us4-1-million\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Mesoblast Reports Ryoncil\u00ae Net Revenues of US$30.3m and Improved Net Operating Cash Spend for the Quarter to US$4.1 Million\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Mesoblast Reports Ryoncil\u00ae Net Revenues of US$30.3m and Improved Net Operating Cash Spend for the Quarter to US$4.1 Million - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/mesoblast-reports-ryoncil-net-revenues-of-us30-3m-and-improved-net-operating-cash-spend-for-the-quarter-to-us4-1-million\/","og_locale":"en_US","og_type":"article","og_title":"Mesoblast Reports Ryoncil\u00ae Net Revenues of US$30.3m and Improved Net Operating Cash Spend for the Quarter to US$4.1 Million - Market Newsdesk","og_description":"Achieved Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain Activity Report for Quarter Ended March 31, 2026 (Appendix 4C) NEW YORK, April 29, 2026 (GLOBE NEWSWIRE) &#8212; Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided highlights of its recent activities for the third fiscal quarter ended March 31, 2026. \u201cWe\u2019ve had a busy and exciting March quarter marked by a series of major achievements. Ryoncil\u00ae revenues are now approaching US$100 million since last year\u2019s launch, we have substantially improved our net operating cash spend, our pivotal trial in inflammatory back pain has successfully achieved its patient recruitment target, and we have bolstered our long-term leadership in the field &hellip; Continue reading \"Mesoblast Reports Ryoncil\u00ae Net Revenues of US$30.3m and Improved Net Operating Cash Spend for the Quarter to US$4.1 Million\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/mesoblast-reports-ryoncil-net-revenues-of-us30-3m-and-improved-net-operating-cash-spend-for-the-quarter-to-us4-1-million\/","og_site_name":"Market Newsdesk","article_published_time":"2026-04-30T00:58:02+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxMDE0MCM3NTc0ODI3IzIwMTc0MzI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mesoblast-reports-ryoncil-net-revenues-of-us30-3m-and-improved-net-operating-cash-spend-for-the-quarter-to-us4-1-million\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mesoblast-reports-ryoncil-net-revenues-of-us30-3m-and-improved-net-operating-cash-spend-for-the-quarter-to-us4-1-million\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Mesoblast Reports Ryoncil\u00ae Net Revenues of US$30.3m and Improved Net Operating Cash Spend for the Quarter to US$4.1 Million","datePublished":"2026-04-30T00:58:02+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mesoblast-reports-ryoncil-net-revenues-of-us30-3m-and-improved-net-operating-cash-spend-for-the-quarter-to-us4-1-million\/"},"wordCount":1399,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mesoblast-reports-ryoncil-net-revenues-of-us30-3m-and-improved-net-operating-cash-spend-for-the-quarter-to-us4-1-million\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxMDE0MCM3NTc0ODI3IzIwMTc0MzI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mesoblast-reports-ryoncil-net-revenues-of-us30-3m-and-improved-net-operating-cash-spend-for-the-quarter-to-us4-1-million\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/mesoblast-reports-ryoncil-net-revenues-of-us30-3m-and-improved-net-operating-cash-spend-for-the-quarter-to-us4-1-million\/","name":"Mesoblast Reports Ryoncil\u00ae Net Revenues of US$30.3m and Improved Net Operating Cash Spend for the Quarter to US$4.1 Million - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mesoblast-reports-ryoncil-net-revenues-of-us30-3m-and-improved-net-operating-cash-spend-for-the-quarter-to-us4-1-million\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mesoblast-reports-ryoncil-net-revenues-of-us30-3m-and-improved-net-operating-cash-spend-for-the-quarter-to-us4-1-million\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxMDE0MCM3NTc0ODI3IzIwMTc0MzI=","datePublished":"2026-04-30T00:58:02+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mesoblast-reports-ryoncil-net-revenues-of-us30-3m-and-improved-net-operating-cash-spend-for-the-quarter-to-us4-1-million\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/mesoblast-reports-ryoncil-net-revenues-of-us30-3m-and-improved-net-operating-cash-spend-for-the-quarter-to-us4-1-million\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mesoblast-reports-ryoncil-net-revenues-of-us30-3m-and-improved-net-operating-cash-spend-for-the-quarter-to-us4-1-million\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxMDE0MCM3NTc0ODI3IzIwMTc0MzI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxMDE0MCM3NTc0ODI3IzIwMTc0MzI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mesoblast-reports-ryoncil-net-revenues-of-us30-3m-and-improved-net-operating-cash-spend-for-the-quarter-to-us4-1-million\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Mesoblast Reports Ryoncil\u00ae Net Revenues of US$30.3m and Improved Net Operating Cash Spend for the Quarter to US$4.1 Million"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/956320","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=956320"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/956320\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=956320"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=956320"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=956320"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}